HK1244460A1 - Serpin fusion polypeptides and methods of use thereof - Google Patents

Serpin fusion polypeptides and methods of use thereof

Info

Publication number: HK1244460A1
Authority: HK; Hong Kong
Prior art keywords: methods; fusion polypeptides; serpin fusion; serpin; polypeptides
Prior art date: 2014-10-27

Application number

HK18103148.5A

Other languages

Chinese (zh)

Inventor

Brendan P Eckelman

John C Timmer

Quinn Deveraux

Original Assignee

Inhibrx Lp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-27

Filing date

2018-03-05

Publication date

2018-08-10

2014-10-27 Priority claimed from US14/524,832 external-priority patent/US10400029B2/en

2018-03-05 Application filed by Inhibrx Lp filed Critical Inhibrx Lp

2018-08-10 Publication of HK1244460A1 publication Critical patent/HK1244460A1/en

Links

102000008847 Serpin Human genes 0.000 title 1
108050000761 Serpin Proteins 0.000 title 1
230000004927 fusion Effects 0.000 title 1
229920001184 polypeptide Polymers 0.000 title 1
102000004196 processed proteins & peptides Human genes 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1
239000003001 serine protease inhibitor Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Hematology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Virology (AREA)
Transplantation (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)

HK18103148.5A 2014-10-27 2018-03-05 Serpin fusion polypeptides and methods of use thereof HK1244460A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US14/524,832 US10400029B2 (en)	2011-06-28	2014-10-27	Serpin fusion polypeptides and methods of use thereof
PCT/US2015/057533 WO2016069574A1 (en)	2014-10-27	2015-10-27	Serpin fusion polypeptides and methods of use thereof

Publications (1)

Publication Number	Publication Date
HK1244460A1 true HK1244460A1 (en)	2018-08-10

Family

ID=55858243

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18103148.5A HK1244460A1 (en)	2014-10-27	2018-03-05	Serpin fusion polypeptides and methods of use thereof

Country Status (14)

Country	Link
EP (1)	EP3212290A4 (en)
JP (2)	JP6737781B2 (en)
KR (2)	KR20170091096A (en)
CN (2)	CN114316068A (en)
AU (3)	AU2015339507B2 (en)
BR (1)	BR112017008525A2 (en)
CA (1)	CA2965151A1 (en)
HK (1)	HK1244460A1 (en)
IL (2)	IL251799B2 (en)
MX (2)	MX2017005467A (en)
RU (1)	RU2746550C2 (en)
SG (2)	SG10201903142RA (en)
UA (1)	UA127305C2 (en)
WO (1)	WO2016069574A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA3117961A1 (en) *	2018-10-29	2020-05-07	Spin Therapeutics, Llc	Compositions and methods for alpha-1-antitrypsin disorders
CN111989340A (en) *	2018-11-18	2020-11-24	杭州博虎生物科技有限公司	Recombinant human interleukin 10 fusion protein and application thereof
CN112315897A (en) *	2020-11-04	2021-02-05	深圳前海鹰岗生物科技有限公司	Polymer microneedle for treating acute gout attack by inhibiting release of cell inflammatory reaction and preparation method
WO2022133521A1 (en) *	2020-12-21	2022-06-30	Macquarie University	Treatment of glaucoma
GB202102258D0 (en) *	2021-02-17	2021-03-31	Arecor Ltd	Novel composition
CA3205815A1 (en) *	2021-03-03	2022-09-09	Alwin REITER	Formulations of ace2 fc fusion proteins
CN113325181A (en) *	2021-04-25	2021-08-31	苏州市立医院(北区)	Application of serine protease inhibitor in marker for early warning of sepsis
CN114874333A (en) *	2021-10-18	2022-08-09	深圳科兴药业有限公司	Growth hormone fusion protein and application thereof
TW202409072A (en)	2022-05-16	2024-03-01	美商英伊布里克斯公司	Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2364471A1 (en) *	1999-03-01	2000-09-08	Human Genome Sciences, Inc.	Human serpin proteins
US7317091B2 (en) *	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US7217797B2 (en) *	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
EP1646642A2 (en) *	2003-07-18	2006-04-19	Vertex Pharmaceuticals Incorporated	Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
EP3192872A1 (en) *	2003-08-26	2017-07-19	The Regents of the University of Colorado, a body corporate	Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
US8802820B2 (en) *	2004-11-12	2014-08-12	Xencor, Inc.	Fc variants with altered binding to FcRn
KR101027427B1 (en) *	2004-11-12	2011-04-11	젠코어 인코포레이티드	Fc VARIANTS WITH INCREASED BINDING TO FcRn
EP2083081A1 (en) *	2005-07-22	2009-07-29	Five Prime Therapeutics, Inc.	Compositions and methods of treating disease with FGFR fusion proteins
MX2008002101A (en) *	2005-08-12	2008-04-19	Schering Corp	Mcp1 fusions.
CA2729012A1 (en) *	2008-06-27	2009-12-30	Amgen Inc.	Ang-2 inhibition to treat multiple sclerosis
EP2786762B1 (en) *	2008-12-19	2019-01-30	MacroGenics, Inc.	Covalent diabodies and uses thereof
SG191233A1 (en) *	2010-12-23	2013-07-31	Janssen Biotech Inc	Active protease-resistant antibody fc mutants
CN103476795B (en) *	2011-03-29	2016-07-06	罗切格利卡特公司	Antibody Fc variant
SG10201601621PA (en) *	2011-06-28	2016-04-28	Inhibrx Llc	Serpin fusion polypeptides and methods of use thereof
CA2839622A1 (en) *	2011-06-28	2013-01-03	Inhibrx Llc	Wap domain fusion polypeptides and methods of use thereof
WO2013106589A1 (en) *	2012-01-10	2013-07-18	The Regents Of The University Of Colorado, A Body Corporate	Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
EP2863954A1 (en) *	2012-06-21	2015-04-29	Indiana University Research and Technology Corporation	Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
BR112014028368A2 (en) *	2012-06-27	2017-11-14	Hoffmann La Roche	method of producing antibody fc region conjugate, antibody fc region conjugate and pharmaceutical formulation
BR112015002263A2 (en) *	2012-08-02	2017-12-12	Hoffmann La Roche	fusion polypeptide, dimeric fusion polypeptide, method for producing a soluble fc receptor, use of an immobilized fusion polypeptide and pharmaceutical composition
JP6345688B2 (en) *	2012-12-05	2018-06-20	ソラ・バイオサイエンシズ・エルエルシー	Protein expression enhancing polypeptide

2015
- 2015-10-27 CA CA2965151A patent/CA2965151A1/en active Pending
- 2015-10-27 BR BR112017008525-9A patent/BR112017008525A2/en active Search and Examination
- 2015-10-27 SG SG10201903142RA patent/SG10201903142RA/en unknown
- 2015-10-27 KR KR1020177014414A patent/KR20170091096A/en not_active IP Right Cessation
- 2015-10-27 AU AU2015339507A patent/AU2015339507B2/en active Active
- 2015-10-27 CN CN202111439584.9A patent/CN114316068A/en active Pending
- 2015-10-27 WO PCT/US2015/057533 patent/WO2016069574A1/en active Application Filing
- 2015-10-27 UA UAA201705128A patent/UA127305C2/en unknown
- 2015-10-27 KR KR1020237043666A patent/KR20240005109A/en active Application Filing
- 2015-10-27 EP EP15854670.5A patent/EP3212290A4/en active Pending
- 2015-10-27 RU RU2017118325A patent/RU2746550C2/en active
- 2015-10-27 IL IL251799A patent/IL251799B2/en unknown
- 2015-10-27 MX MX2017005467A patent/MX2017005467A/en unknown
- 2015-10-27 IL IL308589A patent/IL308589A/en unknown
- 2015-10-27 JP JP2017522654A patent/JP6737781B2/en active Active
- 2015-10-27 SG SG11201703390SA patent/SG11201703390SA/en unknown
- 2015-10-27 CN CN201580071331.7A patent/CN107206257A/en active Pending
2017
- 2017-04-26 MX MX2021012047A patent/MX2021012047A/en unknown
2018
- 2018-03-05 HK HK18103148.5A patent/HK1244460A1/en unknown
2020
- 2020-07-16 JP JP2020121953A patent/JP2020180157A/en active Pending
2021
- 2021-09-28 AU AU2021240153A patent/AU2021240153A1/en not_active Abandoned
2024
- 2024-05-29 AU AU2024203586A patent/AU2024203586A1/en active Pending

Also Published As

Publication number	Publication date
AU2024203586A1 (en)	2024-06-20
BR112017008525A2 (en)	2018-01-30
CA2965151A1 (en)	2016-05-06
RU2746550C2 (en)	2021-04-15
JP2017537888A (en)	2017-12-21
WO2016069574A1 (en)	2016-05-06
IL308589A (en)	2024-01-01
KR20170091096A (en)	2017-08-08
KR20240005109A (en)	2024-01-11
JP2020180157A (en)	2020-11-05
RU2017118325A (en)	2018-11-29
RU2017118325A3 (en)	2019-03-21
IL251799B2 (en)	2024-04-01
AU2015339507A1 (en)	2017-05-11
EP3212290A1 (en)	2017-09-06
SG10201903142RA (en)	2019-05-30
AU2021240153A1 (en)	2021-10-28
AU2015339507B2 (en)	2021-07-01
CN114316068A (en)	2022-04-12
CN107206257A (en)	2017-09-26
IL251799B1 (en)	2023-12-01
MX2017005467A (en)	2017-11-30
MX2021012047A (en)	2021-11-03
EP3212290A4 (en)	2019-01-23
IL251799A0 (en)	2017-06-29
UA127305C2 (en)	2023-07-19
JP6737781B2 (en)	2020-08-12
SG11201703390SA (en)	2017-05-30

Publication	Publication Date	Title
IL275307B (en)	2022-03-01	Syntac polypeptides and uses thereof
IL281273A (en)	2021-04-29	Modified fgf-21 polypeptides and uses thereof
HRP20190028T1 (en)	2019-02-22	Interleukin-2 fusion proteins and uses thereof
IL250415B (en)	2020-09-30	Anti-pdl- antibodies and methods of use thereof
GB201509062D0 (en)	2015-07-08	OX40L fusion proteins and uses thereof
IL262727A (en)	2018-12-31	Cd40l-fc fusion polypeptides and methods of use thereof
HK1244460A1 (en)	2018-08-10	Serpin fusion polypeptides and methods of use thereof
GB201404470D0 (en)	2014-04-30	Therapeutic methods and materials
EP3349851A4 (en)	2019-04-24	Light-responsive polypeptides and methods of use thereof
EP3092248A4 (en)	2017-06-28	Fusion polypeptides and methods of use
GB201410031D0 (en)	2014-07-16	Polypeptides and uses thereof
EP3322736A4 (en)	2019-02-20	Fusion polypeptides and methods of use
IL247448A0 (en)	2016-11-30	Peptides and methods of use
SG11201610918RA (en)	2017-01-27	Peptides and uses thereof
RS62066B1 (en)	2021-07-30	Modified fgf-21 polypeptides and uses thereof